-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a new study, researchers from the Rush University Medical Center in the United States have made new progress in the treatment of Parkinson’s disease: the potential new treatment for Parkinson’s disease they developed has shown to slow the progression of the disease in mice.
Specifically, the authors found that two different peptides help slow the spread of alpha-synuclein, an abnormal protein deposit called Lewy body in the brain.
Lewy bodies are also related to dementia with Lewy bodies and a rare neurological disease---multiple system atrophy (MSA)
The activation of NF-κB increases the expression of α-synuclein in neurons
The two peptides tested in this new study are called Myd88's TLR2 interaction domain (TLR2-interacting domain, TIDM) and NEMO-binding domain (NEMO-binding domain, NBD)
Note: The original text has been deleted
Reference materials:
Debashis Dutta et al.